Vera Therapeutics, Inc. Class A VERA 深 沪
已收盘 03-27 16:00:00 美东时间
38.86
-1.400
-3.48%
华盛通- 最 高40.47
- 今 开39.88
- 成交量 76.32万股
- 最 低 38.165
- 昨 收 40.26
- 总市值 27.73亿
- 52周最高 56.05
- 市盈率 静 --
- 换手率 1.07%
- 52周最低 18.53
- 委 比 87.91%
- 总股本 7135.57万
- 历史最高 56.05
- 量 比 0.45
- 振 幅 5.73%
- 历史最低 5.20
- 每 手 1
- 风险率 10.08%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics授予新任首席法律顾问Jane Wright-Mitchell股票期权和限制性股票单位（RSUs），总计101,253股A类普通股，以吸引其加入。期权行权价为每股40.73美元，基于2026年3月23日的收盘价，分四年归属。RSU则于2026年5月20日起每年归属25%，激励新员工长期服务。Vera是一家专注于开发免疫疾病治疗的临床后期生物科技公司，其主要候选药物atacicept针对多种自身免疫性疾病。
03-27 20:05
Vera Therapeutics appoints Jane Wright-Mitchell chief legal officer
Vera Therapeutics appoints Jane Wright-Mitchell chief legal officer Vera Therapeutics appointed Jane Wright-Mitchell as Chief Legal Officer, effective immediately. Wright-Mitchell previously served as a fractional general counsel supporting public and private life sciences companies. Her prior roles
03-25 19:30
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
Vera Therapeutics appoints Jane Wright-Mitchell, Pharm.D., J.D., as Chief Legal Officer, leveraging her over 25 years of experience in legal and compliance matters within the life sciences industry. Her expertise will support Vera’s upcoming commercial launch of atacicept, a dual BAFF/APRIL inhibitor for IgA nephropathy, and strengthen the company’s legal framework. Wright-Mitchell previously served as General Counsel at Vaxcyte, Inc. and brings ...
03-25 11:30
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
Wolfe Research Upgrades Vera Therapeutics to Outperform, Announces $88 Price Target
Wolfe Research analyst Andy Chen upgrades Vera Therapeutics (NASDAQ:VERA) from Peer Perform to Outperform and announces $88 price target.
03-11 19:45
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics granted inducement awards, including non-qualified stock options for 46,000 shares and RSUs for 25,875 shares, to six new employees under its 2024 Inducement Plan. The stock options and RSUs vest over four years, with specific vesting schedules tied to continued employment. Vera Therapeutics is a biotech company focused on developing treatments for serious immunological diseases, including its lead candidate atacicept, which tar...
03-06 21:05
BRIEF-Vera Therapeutics Appoints Christopher Hite To Board Of Directors
BRIEF-Vera Therapeutics Appoints Christopher Hite To Board Of Directors March 5 (Reuters) - Vera Therapeutics Inc VERA.O : VERA THERAPEUTICS APPOINTS CHRISTOPHER HITE TO BOARD OF DIRECTORS Source text: ID:nGNX3n8PVS Further company coverage: VERA.O (( Reuters.Briefs@thomsonreuters.com ;))
03-05 22:01
美股大行评级 | 花旗：维持康菲石油"买入"评级！目标价从125美元升至135美元
今日重点评级关注：HC Wainwright & Co.：维持Helus Pharma"买入"评级，目标价从55美元升至95美元；HC Wainwright & Co.：维持Compass Pathways"买入"评级，目标价从40美元升至70美元
03-03 20:22
HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Raises Price Target to $110
HC Wainwright & Co. analyst Arthur He maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and raises the price target from $90 to $110.
03-02 20:43
财报速睇 | Vera Therapeutics, Inc. Class A 2025财年年度营收0.00亿美元，同比增长0.0%；归母净利润亏损3.00亿美元，同比亏损扩大96.9%
华盛资讯2月27日讯，Vera Therapeutics, Inc. Class A公布2025财年年度业绩，公司年度营收0.00亿美元，同比增长0.0%，归母净利润亏损3.00亿美元，同比亏损扩大96.9%。
02-27 09:01
